| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Epidemiology and Prevention |
Department of Medicine, Weill Medical College of Cornell University, New York, New York
Requests for reprints: Kotha Subbaramaiah, New York Presbyterian Hospital-Cornell, 525 East 68th Street, Room F-203A, New York, NY 10021. Phone: 212-746-4402; Fax: 212-746-4885; E-mail: ksubba{at}med.cornell.edu.
Cyclooxygenase (COX-2) is overexpressed in human papillomavirus (HPV)-induced diseases, including cervical cancer. Although HPV E6 and E7 oncoproteins have been causally linked to cervical carcinogenesis, their effects on COX-2 gene expression are unknown. Increased levels of COX-2 mRNA, protein, and prostaglandin E2 synthesis were detected in HPV16 E6- and E7-expressing cervical cancer cells (CaSki and SiHa) compared with an uninfected cervical cancer cell line (C33A). HPV16 E6 and E7 oncoproteins induced COX-2 transcription by activating the epidermal growth factor receptor (EGFR)
Ras
mitogen-activated protein kinase pathway. Interestingly, HPV16 oncoproteins stimulated EGFR signaling, in part, by inducing the release of amphiregulin, an EGFR ligand. The inductive effects of HPV16 E6 and E7 were mediated by enhanced binding of activator protein-1 to the cyclic AMP (cAMP)-responsive element (59/53) of the COX-2 promoter. The potential contribution of coactivators and corepressors to HPV16 E6- and E7-mediated induction of COX-2 was also investigated. Chromatin immunoprecipitation assays indicated that E6 and E7 oncoproteins induced the recruitment of phosphorylated c-Jun, c-Fos, UbcH5, and cAMP-responsive element binding proteinbinding protein/p300 to the COX-2 promoter. In contrast, E6 and E7 inhibited the binding of the histone deacetylase 3-nuclear receptor corepressor (NCoR) complex to the COX-2 promoter. Moreover, overexpression of NCoR blocked E6- and E7-mediated stimulation of the COX-2 promoter. Taken together, these results indicate that HPV16 E6 and E7 oncoproteins stimulated COX-2 transcription by inducing a corepressor/coactivator exchange. To our knowledge, this study also provides the first evidence that NCoR can function as a repressor of COX-2 gene expression. [Cancer Res 2007;67(8):397685]
This article has been cited by other articles:
![]() |
H. N Jabbour, K. J Sales, R. D Catalano, and J. E Norman Inflammatory pathways in female reproductive health and disease Reproduction, December 1, 2009; 138(6): 903 - 919. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. R. Coward, K. Watts, C. A. Feghali-Bostwick, A. Knox, and L. Pang Defective Histone Acetylation Is Responsible for the Diminished Expression of Cyclooxygenase 2 in Idiopathic Pulmonary Fibrosis Mol. Cell. Biol., August 1, 2009; 29(15): 4325 - 4339. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. M. Kim, S.-Y. Park, and H. Pyo Cyclooxygenase-2 (COX-2) Negatively Regulates Expression of Epidermal Growth Factor Receptor and Causes Resistance to Gefitinib in COX-2-Overexpressing Cancer Cells Mol. Cancer Res., August 1, 2009; 7(8): 1367 - 1377. [Abstract] [Full Text] [PDF] |
||||
![]() |
S.-H. Kim, J.-M. Oh, J.-H. No, Y.-J. Bang, Y.-S. Juhnn, and Y.-S. Song Involvement of NF-{kappa}B and AP-1 in COX-2 upregulation by human papillomavirus 16 E5 oncoprotein Carcinogenesis, May 1, 2009; 30(5): 753 - 757. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-M. Oh, S.-H. Kim, Y.-I. Lee, M. Seo, S.-Y. Kim, Y.-S. Song, W.-H. Kim, and Y.-S. Juhnn Human papillomavirus E5 protein induces expression of the EP4 subtype of prostaglandin E2 receptor in cyclic AMP response element-dependent pathways in cervical cancer cells Carcinogenesis, January 1, 2009; 30(1): 141 - 149. [Abstract] [Full Text] [PDF] |
||||
![]() |
W.-L. Wang, Y.-C. Lee, W.-M. Yang, W.-C. Chang, and J.-M. Wang Sumoylation of LAP1 is involved in the HDAC4-mediated repression of COX-2 transcription Nucleic Acids Res., November 1, 2008; 36(19): 6066 - 6079. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Fosslien Cancer Morphogenesis: Role of Mitochondrial Failure Ann. Clin. Lab. Sci., January 1, 2008; 38(4): 307 - 330. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |